Medical policy: Electrical Bone Growth Stimulation of the Appendicular Skeleton

Policy number: MP 1.024

Clinical benefit

  • Minimize safety risk or concern.
  • Minimize harmful or ineffective interventions.
  • Assure appropriate level of care.
  • Assure appropriate duration of service for interventions.
  • Assure that recommended medical prerequisites have been met.
  • Assure appropriate site of treatment or service.

Effective date: 9/1/2026

Policy

Noninvasive electrical bone growth stimulation may be considered medically necessary for the treatment of fracture nonunions or congenital pseudoarthrosis in the appendicular skeleton (the appendicular skeleton includes the bones of the shoulder girdle, upper extremities, pelvis, and lower extremities). The diagnosis of fracture nonunion must meet ALL of the following criteria:

  • at least 3 months have passed since the date of fracture;
  • serial radiographs have confirmed that no progressive signs of healing have occurred;
  • the fracture gap is 1 cm or less;
  • the individual can be adequately immobilized; and
  • the individual is of an age likely to comply with nonweight bearing for fractures of the pelvis and lower extremities.

Investigational applications of electrical bone growth stimulation include, but are not limited to, delayed union, fresh fracture, stress fractures, immediate postsurgical treatment after appendicular skeletal surgery, arthrodesis, or failed arthrodesis. There is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with this procedure.

Implantable and semi-invasive electrical bone growth stimulators are considered investigational. There is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with these procedures.

Policy guidelines

Fracture Nonunion

No consensus on the definition of fracture nonunion currently exists. One proposed definition is failure of progression of fracture healing for at least 3 consecutive months (and for at least 6 months following the fracture), accompanied by clinical symptoms of delayed union or nonunion (pain, difficulty bearing weight) (Bhandari et al, 2012).

The original U.S. Food and Drug Administration (FDA) labeling of fracture nonunions defined them as fractures that had not shown progressive healing after at least 9 months from the original injury. The labeling states: “A nonunion is considered to be established when a minimum of 9 months has elapsed since injury and the fracture site shows no visibly progressive signs of healing for minimum of 3 months.” This timeframe is not based on physiologic principles but was included as part of the research design for FDA approval as a means of ensuring homogeneous populations of patients, many of whom were serving as their own controls. Others have contended that 9 months represents an arbitrary cutoff point that does not reflect the complicated variables that are present in fractures (i.e., degree of soft tissue damage, alignment of the bone fragments, vascularity, and quality of the underlying bone stock). Some fractures may show no signs of healing, based on serial radiographs, as early as 3 months, while a fracture nonunion may not be diagnosed in others until well after 9 months. The current policy of requiring a 3-month timeframe for lack of progression of healing is consistent with the definition of nonunion as described in the clinical literature.

Delayed Union

Delayed union is defined as a decelerating healing process as determined by serial radiographs, together with a lack of clinical and radiologic evidence of union, bony continuity, or bone reaction at the fracture site for no less than 3 months from the index injury or the most recent intervention. In contrast, nonunion serial radiographs (described above) show no evidence of healing. When lumped together, delayed union and nonunion are sometimes referred to as “ununited fractures.”

Fresh Fracture

A fracture is most commonly defined as “fresh” for 7 days after its occurrence. Most fresh closed fractures heal without complications with the use of standard fracture care (i.e., closed reduction, cast immobilization).

Cross-references:

  • MP 1.150 Electrical Stimulation of the Spine as an Adjunct to Spinal Fusion Procedures
  • MP 6.021 Low Intensity Pulsed Ultrasound Fracture Healing Device

Product variations

This policy is only applicable to certain programs and products administered by Capital Blue Cross and subject to benefit variations. Please see additional information below.

FEP PPO - Refer to FEP Medical Policy Manual. The FEP Medical Policy manual can be found at: FEP Medical Policy Manual.

Description/Background

Treatment of Delayed and Nonunion Fractures

Individuals with recognized delayed fracture unions might begin by reducing the risk factors for delayed unions or nonunions but may progress to surgical repair if it persists.

Electrical and Electromagnetic Bone Growth Stimulators

Different applications of electrical and electromagnetic fields have been used to promote healing of delayed and nonunion fractures: invasive, noninvasive, and semi-invasive.

Invasive Stimulators

Invasive stimulation involves the surgical implantation of a cathode at the fracture site to produce direct current electrical stimulation. Invasive devices require surgical implantation of a current generator in an intramuscular or subcutaneous space, while an electrode is implanted within the fragments of bone graft at the fusion site. The implantable device typically remains functional for 6 to 9 months after implantation, and although the current generator is removed in a second surgical procedure when stimulation is completed, the electrode may or may not be removed. Implantable electrodes provide constant stimulation at the nonunion or fracture site but carry increased risks associated with implantable leads.

Noninvasive Stimulators

Noninvasive electrical bone growth stimulators generate a weak electrical current within the target site using pulsed electromagnetic fields, capacitive coupling, or combined magnetic fields. In capacitive coupling, small skin pads/electrodes are placed on either side of the fusion site and worn for 24 hours a day until healing occurs or up to 9 months. In contrast, pulsed electromagnetic fields are delivered via treatment coils placed over the skin and worn for 6 to 8 hours a day for 3 to 6 months. Combined magnetic fields deliver a time-varying magnetic field by superimposing the time-varying magnetic field onto an additional static magnetic field. This device involves a 30-minute treatment per day for 9 months. Patient compliance may be an issue with externally worn devices.

Semi-Invasive Stimulators

Semi-invasive (semi-implantable) stimulators use percutaneous electrodes and an external power supply, obviating the need for a surgical procedure to remove the generator when treatment is finished.

Regulatory Status

Table 1 summarizes the FDA cleared or approved electrical bone growth stimulator devices. No semi-invasive electrical bone growth stimulator devices with the FDA approval or clearance were identified.

The FDA has approved labeling changes for electrical bone growth stimulators that remove any time frame for the diagnosis. In September 2020, FDA considered the reclassification of noninvasive electrical bone growth stimulators from Class 3 to the lower-risk Class 2 category. As of March 2026, however, the devices remain Class 3.

FDA product code LOF.

Table 1. U.S. Food and Drug Administration-Approved Electrical Bone Growth Stimulator Devices

Device
Indication
Manufacturer
Date approved
PMA No. / Device code

BIO Osteogen System 204 (now EBI Bone Healing System)

Indicated for the treatment of a variety of conditions, including nonunions, congenital pseudoarthrosis, and certain fractures.

EBI (now Highridge Medical)

1979

P790002

OrthoPak Non-invasive Bone Growth Stimulator System

Indicated for the treatment of an established nonunion acquired secondary to trauma, excluding vertebrae and all flat bones.

EBI (now Highridge Medical)

1986

P850022/S018

Physio-Stim®

Indicated for the treatment of an established nonunion acquired secondary to trauma, excluding vertebrae and all flat bones.

Orthofix

1986

P850007

OrthoLogic (TM) 1000 Bone Growth Stimulator

Indicated for the noninvasive treatment of an established nonunion acquired secondary to trauma, excluding vertebrae and all flat bones.

DJO (now Enovis)

1994

P910066

Osteogen(R) D40 Implantable Bone Growth Stimulator

Indicated for treatment of nonunions of long bones.

EBI (now Highridge Medical)

2000

P790005

Rationale

Summary of evidence

Noninvasive Electrical Bone Growth Stimulation

For individuals who have fracture nonunion who receive noninvasive electrical bone growth stimulation, the evidence includes randomized controlled trials (RCTs) and systematic reviews of RCTs. Relevant outcomes are symptoms, change in disease status, and functional outcomes. The U.S. Food and Drug Administration has approved noninvasive electrical bone growth stimulation for fracture nonunions, congenital pseudoarthrosis, and failed fusions in the appendicular skeleton, based largely on studies with patients serving as their controls. There is also evidence from 2 small sham-controlled randomized trials that noninvasive electrical stimulators improve fracture healing for patients with fracture nonunion. There are few nonsurgical options in this population, and the pre-post studies of patients with nonhealing fractures support the efficacy of the treatment. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have delayed fracture union who receive noninvasive electrical bone growth stimulation, the evidence includes RCTs and systematic reviews of RCTs. Relevant outcomes are symptoms, change in disease status, and functional outcomes. RCTs on the delayed union of fractures were limited by small sample sizes and did not show significant differences in outcomes between study groups. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have fresh fracture(s) who receive noninvasive electrical bone growth stimulation, the evidence includes RCTs and systematic reviews of RCTs. Relevant outcomes are symptoms, change in disease status, and functional outcomes. A meta-analysis of 5 RCTs found no statistically significant benefit of electrical bone growth stimulation for fresh fractures. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have stress fracture(s) who receive noninvasive electrical bone growth stimulation, the evidence includes an RCT. Relevant outcomes are symptoms, change in disease status, and functional outcomes. This well-conducted RCT found that, although an increase in the hours of use per day was associated with a reduction in the time to healing, there was no difference in the rate of healing between treatment and placebo. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have had surgery of the appendicular skeleton who receive noninvasive electrical bone growth stimulation, the evidence includes 2 small RCTs. Relevant outcomes are symptoms, change in disease status, and functional outcomes. Although the results of 1 trial suggest benefits to the bone stimulation in decreased time to union, clinical outcomes were not assessed. The evidence is insufficient to determine the effects of the technology on health outcomes.

Implantable and Semi-Invasive Bone Growth Stimulation

For individuals who have fracture, pseudoarthrosis, or who have had surgery of the appendicular skeleton who receive implantable and semi-invasive electrical bone growth stimulation, the evidence includes a small number of case series. Relevant outcomes are symptoms, change in disease status, and functional outcomes. The evidence is insufficient to determine the effects of the technology on health outcomes.

Definitions

Appendicular Skeleton consists of the bones of the limbs and their girdles, attached to the axial skeleton.

Axial Skeleton consists of bones in the head and trunk of the human body. It is composed of five parts: the human skull, the ossicles of the inner ear, the hyoid bone of the throat, the rib cage, and the vertebral column.

Disclaimer

Capital Blue Cross’ medical policies are used to determine coverage for specific medical technologies, procedures, equipment, and services. These medical policies do not constitute medical advice and are subject to change as permitted by law or applicable clinical evidence from independent treatment guidelines. Treating providers are solely responsible for medical advice and treatment of members. These policies are not a guarantee of coverage or payment. Payment of claims is subject to a determination regarding the member’s benefit program and eligibility on the date of service, and a determination that the services are medically necessary and appropriate. Final processing of a claim is based upon the terms of contract that applies to the members’ benefit program, including benefit limitations and exclusions. If a provider or a member has a question concerning this medical policy, please contact Capital Blue Cross’ Provider Services or Member Services.

Coding information

Note: This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

Investigational; therefore, not covered, implantable and semi-invasive electrical bone growth stimulation:

Procedure codes

20975

E0749

 

 

 

Covered when medically necessary, noninvasive electrical bone growth stimulation:

Procedure codes

20974

E0747

 

 

 

ICD-10-CM diagnosis code
Description

Q74.0

Other congenital malformations of upper limb(s), including shoulder girdle

Q74.2

Other congenital malformations of lower limb(s), including pelvic girdle

Note: Any fracture diagnosis could potentially meet criteria.

References

  1. U.S. Food and Drug Administration (FDA). Summary Minutes: Center for Devices and Radiological Health Orthopaedic and Rehabilitation Devices Panel (2020). Accessed March 17, 2026.
  2. Bhandari M, Fong K, Sprague S, et al. Variability in the definition and perceived causes of delayed unions and nonunions: a cross-sectional, multinational survey of orthopaedic surgeons. J Bone Joint Surg Am. Aug 01 2012; 94(15): e1091-6. PMID 22854998
  3. Buza JA, Einhorn T. Bone healing in 2016. Clin Cases Miner Bone Metab. 2016; 13(2): 101-105. PMID 27920804
  4. Ahl T, Andersson G, Herberts P, et al. Electrical treatment of non-united fractures. Acta Orthop Scand. Dec 1984; 55(6): 585-8. PMID 6335345
  5. Connolly JF. Selection, evaluation and indications for electrical stimulation of ununited fractures. Clin Orthop Relat Res. 1981; (161): 39-53. PMID 6975690
  6. Connolly JF. Electrical treatment of nonunions. Its use and abuse in 100 consecutive fractures. Orthop Clin North Am. Jan 1984; 15(1): 89-106. PMID 6607443
  7. de Haas WG, Beaupre A, Cameron H, et al. The Canadian experience with pulsed magnetic fields in the treatment of ununited tibial fractures. Clin Orthop Relat Res. Jul 1986; (208): 55-8. PMID 3720140
  8. Sharrard WJ, Sutcliffe ML, Robson MJ, et al. The treatment of fibrous non-union of fractures by pulsing electromagnetic stimulation. J Bone Joint Surg Br. 1982; 64(2): 189-93. PMID 6978339
  9. Aleem IS, Aleem I, Evaniew N, et al. Efficacy of Electrical Stimulators for Bone Healing: A Meta-Analysis of Randomized Sham-Controlled Trials. Sci Rep. Aug 19 2016; 6: 31724. PMID 27539550
  10. Simonis RB, Parnell EJ, Ray PS, et al. Electrical treatment of tibial non-union: a prospective, randomised, double-blind trial. Injury. May 2003; 34(5): 357-62. PMID 12719164
  11. Barker AT, Dixon RA, Sharrard WJ, et al. Pulsed magnetic field therapy for tibial non-union. Interim results of a double-blind trial. Lancet. May 05 1984; 1(8384): 994-6. PMID 6143970
  12. Scott G, King JB. A prospective, double-blind trial of electrical capacitive coupling in the treatment of non-union of long bones. J Bone Joint Surg Am. Jun 1994; 76(6): 820-6. PMID 8200888
  13. Shi HF, Xiong J, Chen YX, et al. Early application of pulsed electromagnetic field in the treatment of postoperative delayed union of long-bone fractures: a prospective randomized controlled study. BMC Musculoskelet Disord. Jan 19 2013; 14: 35. PMID 23331333
  14. Sharrard WJ. A double-blind trial of pulsed electromagnetic fields for delayed union of tibial fractures. J Bone Joint Surg Br. May 1990; 72(3): 347-55. PMID 2187877
  15. Griffin XL, Warner F, Costa M. The role of electromagnetic stimulation in the management of established non-union of long bone fractures: what is the evidence?. Injury. Apr 2008; 39(4): 419-29. PMID 18321512
  16. Griffin XL, Costa ML, Parsons N, et al. Electromagnetic field stimulation for treating delayed union or non-union of long bone fractures in adults. Cochrane Database Syst Rev. Apr 13 2011; (4): CD008471. PMID 21491410
  17. Adie S, Harris IA, Naylor JM, et al. Pulsed electromagnetic field stimulation for acute tibial shaft fractures: a multicenter, double-blind, randomized trial. J Bone Joint Surg Am. Sep 07 2011; 93(17): 1569-76. PMID 21915570
  18. Faldini C, Cadossi M, Luciani D, et al. Electromagnetic bone growth stimulation in patients with femoral neck fractures treated with screws: prospective randomized double-blind study. Curr Orthop Pract. 2010; 21(3): 282-287.
  19. Hannemann PF, Göttgens KW, van Wely BJ, et al. The clinical and radiological outcome of pulsed electromagnetic field treatment for acute scaphoid fractures: a randomised double-blind placebo-controlled multicentre trial. J Bone Joint Surg Br. Oct 2012; 94(10): 1403-8. PMID 23015569
  20. Hannemann PF, van Wezenbeek MR, Kolkman KA, et al. CT scan-evaluated outcome of pulsed electromagnetic fields in the treatment of acute scaphoid fractures: a randomized, multicentre, double-blind, placebo-controlled trial. Bone Joint J. Aug 2014; 96-B(8): 1070-6. PMID 25086123
  21. Martinez-Rondanelli A, Martinez JP, Moncada ME, et al. Electromagnetic stimulation as coadjuvant in the healing of diaphyseal femoral fractures: a randomized controlled trial. Colomb Med (Cali). 2014; 45(2): 67-71. PMID 25100891
  22. Beck BR, Matheson GO, Bergman G, et al. Do capacitively coupled electric fields accelerate tibial stress fracture healing? A randomized controlled trial. Am J Sports Med. Mar 2008; 36(3): 545-53. PMID 18055921
  23. Borsalino G, Bagnacani M, Bettati E, et al. Electrical stimulation of human femoral intertrochanteric osteotomies. Double-blind study. Clin Orthop Relat Res. Dec 1988; (237): 256-63. PMID 3191636
  24. Dhawan SK, Conti SF, Towers J, et al. The effect of pulsed electromagnetic fields on hindfoot arthrodesis: a prospective study. J Foot Ankle Surg. 2004; 43(2): 93-6. PMID 15057855
  25. Petrisor B, Lau JT. Electrical bone stimulation: an overview and its use in high risk and Charcot foot and ankle reconstructions. Foot Ankle Clin. Dec 2005; 10(4): 609-20, vii-viii. PMID 16297822
  26. Lau JT, Stamatis ED, Myerson MS, et al. Implantable direct-current bone stimulators in high-risk and revision foot and ankle surgery: a retrospective analysis with outcome assessment. Am J Orthop (Belle Mead NJ). Jul 2007; 36(7): 354-7. PMID 17694182
  27. Saxena A, DiDomenico LA, Widtfeldt A, et al. Implantable electrical bone stimulation for arthrodeses of the foot and ankle in high-risk patients: a multicenter study. J Foot Ankle Surg. 2005; 44(6): 450-4. PMID 16257674
  28. American Academy of Orthopaedic Surgeons (AAOS): Nonunions (May 2024). https://orthoinfo.aaos.org/en/diseases--conditions/nonunions Accessed March 12, 2026.
  29. American Academy of Orthopaedic Surgeons (AAOS): Stress Fractures of the Fifth Metatarsal Base (March 2022). https://orthoinfo.aaos.org/en/diseases--conditions/stress-fractures-of-the-foot-and-ankle/ Accessed March 11, 2026.
  30. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) for Osteogenic Stimulators (150.2). 2005. Accessed March 16, 2026.

Policy history

MP 1.024

06/22/2020 Consensus Review. No change to policy statement. Background, Rationale and References updated.

03/22/2021 Consensus Review. Corrected spelling of pseudarthrosis. No change to policy statement.

05/24/2022 Consensus Review. Reference updates and coding reviewed.

05/23/2023 Consensus Review. Updated background and references. No changes to coding.

05/08/2024 Minor Review. Added failed fusion as additional MN indication. Updated policy guidelines, background, rationale, definitions and references. No changes to coding.

06/06/2025 Minor Review. Removed failed fusion as MN. Updated policy guidelines, background, definitions, and references. Added ICD-10 coding.

04/27/2026 Consensus Review. Updated background and references. No changes to coding.